🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

13 results for “Travere” Clear

  1. Fosmetpantotenate

    Travere Therapeutics

    Pantothenate Kinase-Associated Neurodegeneration

    phase 3 small molecule terminated

    1 trial

  2. IRBESARTAN, DAPAGLIFLOZIN, Sparsentan_DF3, Sparsentan_DF2

    Travere Therapeutics

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  3. Pegtibatinase

    Travere Therapeutics

    Homocystinuria

    phase 3 small molecule active

    3 trials

  4. Pegtibatinase, 0.9 % sodium chloride saline solution (NaCL)

    Travere Therapeutics

    Classical Homocystinuria

    phase 3 small molecule active

    1 trial

  5. Sparsentan_DF2, IRBESARTAN, Sparsentan_DF3

    Travere Therapeutics

    Focal segmental glomerulosclerosis (FSGS)

    phase 3 small molecule active

    1 trial

  6. sparsentan

    Travere Therapeutics

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    3 trials

  7. sparsentan

    Travere Therapeutics

    Focal Segmental Glomerulosclerosis

    phase 3 small molecule active

    2 trials

  8. RE-021 (Sparsentan)

    Travere Therapeutics

    Focal Segmental Glomerulosclerosis

    phase 2 small molecule completed

    1 trial

  9. Sparsentan

    Travere Therapeutics

    ANCA Associated Vasculitis

    phase 2 small molecule active

    1 trial

  10. Sparsentan_DF3, Sparsentan_DF2, Sparsentan_DF4

    Travere Therapeutics

    Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Alport syndrome (AS)

    phase 2 small molecule active

    1 trial

  11. RE-021, sparsentan

    Travere Therapeutics

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  12. sparsentan

    Travere Therapeutics

    Proteinuric Renal Disease

    phase 1 small molecule active

    1 trial

  13. Sparsentan

    Travere Therapeutics

    Proteinuria

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources